To compare the pairwise PK similarities between BAT3306, EU-Keytruda, and US-Keytruda, all administered with pemetrexed and carboplatin. 开始日期2024-07-19 申办/合作机构 百奥泰生物制药股份有限公司 CTR20241959 /Recruiting临床3期 一项评价 BAT3306 联合化疗与可瑞达®联合化疗在 IV 期非小细胞肺癌受试...
The patient was diagnosed with bronchogenic adenocarcinoma and received carboplatin, pemetrexed, and pembrolizumab, which alleviated the esophageal stricture and cancerous lymphangiopathy. However, the adenocarcinoma progressed, and she subsequently received several rounds of chemotherapy. One year after ...
Introduction Pembrolizumab with pemetrexed and cisplatin/carboplatin is an approved first-line treatment for metastatic nonsquamous NSCLC. Nevertheless, its efficacy and safety in patients aged 75 years and above remain unclear. We assessed the efficacy and safety of pembrolizumab with pemetrexed in patien...
Carboplatin/pembrolizumab/pemetrexed. Reactions Weekly 1779, 59 (2019). https://doi.org/10.1007/s40278-019-71323-1 Download citation Published16 November 2019 Issue DateNovember 2019 DOIhttps://doi.org/10.1007/s40278-019-71323-1 Access this article Log in via an institution Subscribe and save...
KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous NSCLC. This indication is approved under accelerated approval based on tumor response rate and progression-free survival. Continued approval for this...
Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study ... Y Kogure,H Hashimoto,M Oki - 《Clinical Lung Cancer》 被引量: 0发表: 2021年 Phase 2 study of pembrolizumab plus pemetrexed for older...
The requested medication will be used as single agent or in combination with pemetrexed for maintenance therapy;or The requested medication will be used in combination with pemetrexed and either carboplatin or cisplatin for nonsquamous cell histology;or ...
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor ab...
The patients will be randomized 1:1 to pembrolizumab (200 mg) or pembrolizumab (200 mg) plus carboplatin (area under the curve 5) plus pemetrexed (500 mg/m2) on day 1 of each 21-day treatment cycle. The primary endpoint is progression-free survival. The recruitment phase began in August...
plus platinum and pemetrexed chemotherapy in metastatic, non-squamous, NSCLC patients in the US.A model is developed utilizing partitioned survival analysis to estimate the cost-effectiveness of KEYNOTE-189 trial comparators pembrolizumab+chemotherapy (carboplatin/cisplatin+pemetrexed) vs chemotherapy alone....